We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This review summarizes current knowledge regarding the possible association between COVID-19 and thrombotic disease and explains how this information should be considered in treating patients with COVID-19 and those without COVID-19 who have thrombotic disease.
The review discusses the pathogenesis and transmission of COVID-19, the relationship between COVID-19 and hemostatic parameters, COVID-19 investigational therapies and implications for thrombotic disease, COVID-19 and venous thromboembolism, COVID-19 and acute coronary syndromes, considerations for patients with critical illness, disseminated intravascular coagulation, and considerations for antithrombotic therapy.
This abstract is available on the publisher's site.
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
JACC: Journal of the American College of Cardiology
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
J Am Coll Cardiol 2020 Apr 17;[EPub Ahead of Print], B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, C Der Nigoghossian, W Ageno, M Madjid, Y Guo, LV Tang, Y Hu, J Giri, M Cushman, I Quéré, EP Dimakakos, CM Gibson, G Lippi, EJ Favaloro, J Fareed, JA Caprini, AJ Tafur, JR Burton, DP Francese, EY Wang, A Falanga, C McLintock, BJ Hunt, AC Spyropoulos, GD Barnes, JW Eikelboom, I Weinberg, S Schulman, M Carrier, G Piazza, JA Beckman, PG Steg, GW Stone, S Rosenkranz, SZ Goldhaber, SA Parikh, M Monreal, HM Krumholz, SV Konstantinides, JI Weitz, GYH Lip